When Should You SELL Your Stocks (8 Reasons to Sell Your Stocks) Click to watch on Youtube.

Adaptimmune Therapeutics plc Stock Forecast

NASDAQ:ADAP BUY

$2.30 (3.60%)

Volume: 216.635k

Closed: Aug 10, 2022

Hollow Logo Score: 2.624

Adaptimmune Therapeutics plc Stock Forecast

BUY NASDAQ:ADAP
$2.30 (3.60%)

Volume: 216.635k

Closed: Aug 10, 2022

Score Hollow Logo 2.624

Adaptimmune Therapeutics plc Company Profile

60 Jubilee Avenue, Milton Park

Abingdon OX14 4RX

44 12 3543 0000

www.adaptimmune.com

Industry: Biotechnology

Sector: Healthcare

Adaptimmune Therapeutics plc

Description

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE